financetom
Business
financetom
/
Business
/
Uber to invest $300 million in EV maker Lucid as part of robotaxi deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Uber to invest $300 million in EV maker Lucid as part of robotaxi deal
Jul 17, 2025 6:08 AM

SAN FRANCISCO (Reuters) -Uber ( UBER ) will invest $300 million in electric vehicle maker Lucid in a robotaxi deal that aims to start with one major U.S. city late next year, the companies said on Thursday.

Shares of Lucid surged more than 56% to $3.58 in trading before the bell after the company also said it had proposed a one-for-ten reverse stock split of its class A common stock.

Over six years starting in 2026, Uber ( UBER ) will acquire and deploy over 20,000 Lucid Gravity SUVs that will be equipped with autonomous vehicle (AV) technology from startup Nuro, the three companies said in a statement.

The agreement illustrates the renewed plans and push for financing for self-driving cabs years after a first wave of autonomous driving investment produced only a limited number of vehicles. Tesla has recently launched a robotaxi trial in Austin and Alphabet's driverless taxi unit Waymo is speeding up its expansion.

As part of their announced deal, Uber ( UBER ) will invest hundreds of millions of dollars in Lucid and Nuro, which supplies self-driving technology to automakers, the joint statement said. Of that, $300 million will go to Lucid, the EV maker said in a separate filing to the U.S. Securities and Exchange Commission on Thursday.

Uber's ( UBER ) latest move underscores its renewed push into the robotaxi space after exiting in 2020. Since then, Uber ( UBER ) has pivoted to partnerships with several technology developers, including Waymo and Aurora.

The deal with Lucid follows Uber's ( UBER ) robotaxi agreement in April with Volkswagen that will supply its ID.Buzz vans for commercial service planned for Los Angeles next year.

But commercializing AV tech has been much harder than anticipated with high costs, tight regulations and federal investigations forcing many, including General Motors' Cruise, to shut down. 

Some still in the race include Amazon.com's Zoox, which is testing a robotaxi without manual controls and plans to launch commercial services in Las Vegas this year.

After years of missed promises, Tesla started a restricted trial with about a dozen of its Model Y SUVs in Austin, Texas, last month. CEO Elon Musk has said it will expand the service rapidly to other U.S. cities this year.

Waymo has been growing cautiously for years and operates in several U.S. cities with about 1,500 vehicles. It crossed 100 million miles of autonomous driving this month. 

A prototype of the Lucid-Nuro robotaxi is already operating autonomously on a closed circuit at Nuro's testing facility in Las Vegas, the companies said. 

"We are expanding beyond our traditional EV technology leadership and working on partnerships and going now into areas that in the past we have not really focused on," Lucid's interim CEO Marc Winterhoff told Reuters.

Nuro, co-founded and led by former Waymo engineers, has expanded from making last-mile delivery vehicles to providing its self-driving technology for commercial and passenger vehicles.

"We have other very active conversations going on the personal vehicle side ... where we would integrate Nuro driver into vehicles that will get sold to end consumers," Dave Ferguson, Nuro's co-founder and president, said. 

Nuro will still need to apply for state-level operating licenses though it holds some licenses from their previous delivery operations, he said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
OpenAI's US ad pilot exceeds $100 million in annualized revenue in six weeks
OpenAI's US ad pilot exceeds $100 million in annualized revenue in six weeks
Mar 26, 2026
March 26 (Reuters) - OpenAI's ChatGPT ads pilot in the United States has crossed the $100 million annualized revenue mark within six weeks of launch, a company spokesperson said on Thursday, pointing to robust early demand for the AI startup's nascent advertising business. Sam Altman-led OpenAI had said in January that it would start showing ads in ChatGPT to some...
OpenAI's US ad pilot exceeds $100 million in annualized revenue in six weeks
OpenAI's US ad pilot exceeds $100 million in annualized revenue in six weeks
Mar 26, 2026
March 26 (Reuters) - OpenAI's ChatGPT ads pilot in the United States has crossed the $100 million annualized revenue mark within six weeks of launch, a company spokesperson said on Thursday, pointing to robust early demand for the AI startup's nascent advertising business. Sam Altman-led OpenAI had said in January that it would start showing ads in ChatGPT to some...
Brown-Forman Confirms Discussions With Pernod Ricard
Brown-Forman Confirms Discussions With Pernod Ricard
Mar 26, 2026
LOUISVILLE, Ky.--(BUSINESS WIRE)-- Brown-Forman Corporation ( BF/A ) today issued the following statement: “We note the recent market rumors regarding a potential business combination involving Brown-Forman ( BF/A ) and Pernod Ricard. Brown-Forman ( BF/A ) regularly explores and evaluates strategic opportunities, and can confirm it is engaged in discussions with Pernod Ricard. If agreed and subject to customary approvals,...
Disc Medicine Completes Enrolment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
Disc Medicine Completes Enrolment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
Mar 26, 2026
05:29 PM EDT, 03/26/2026 (MT Newswires) -- Disc Medicine ( IRON ) said late Thursday the last participant was randomized and dosed in the phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria. The study was expanded to 183 participants from 150 due to patient and physician demand, the company said. Bitopertin is an investigational, clinical-stage, orally administered inhibitor of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved